Acrivon Therapeutics Inc 2024年度报告

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness ofits internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered publicaccounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrantincluded in the filing reflect the correction of an error to previously issued financial statements.☐ Portions of the Registrant's definitive Proxy Statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934,for its 2025 Annual Meeting of Stockholders are incorporated herein by reference in Part III. Table of Contents PART I Item 1.Business4Item 1A.Risk Factors64Item 1B.Unresolved Staff Comments111Item 1C.Cybersecurity111Item 2.Properties112Item 3.Legal Proceedings112Item 4.Mine Safety Disclosures112 Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases ofEquity Securities113Item 6.Reserved113Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations114Item 7A.Quantitative and Qualitative Disclosures About Market Risk126Item 8.Financial Statements and Supplementary Data126Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure126Item 9A.Controls and Procedures126Item 9B.Other Information126Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections127 PART III Item 10.Directors, Executive Officers and Corporate Governance128Item 11.Executive Compensation128Item 12.Security Ownership of Certain Beneficial Owners and Management and Related StockholderMatters128Item 13.Certain Relationships and Related Transactions, and Director Independence128Item 14.Principal Accounting Fees and Services128 PART IV Item 15.Exhibits, Financial Statement Schedules129Item 16.Form 10-K Summary131 Special Note Regarding Forward-Looking Statements This Annual Report on Form 10-K,or the Annual Report, contains forward-looking statements within themeaning of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantialrisks and uncertainties. All statements other than statements of historical facts contained in this Annual Report,including statements regarding our future results of operations or financial condition, business strategy and plansand objectives of management for future operations, are forward-looking statements. In some cases, you can identifyforward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,”“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”or “would” or the negative of these words or other similar terms or expressions. These forward-looking statementsinclude, but are not limited to,statements about the following: •the timing, progress and results of our preclinical studies and clinical trials of our drug candidates,including statements regarding the timing of initiation and completion of studies or trials and relatedpreparatory work, the period during which the results of the trials will become available and ourresearch and development programs;•the timing of any Investigational New Drug, or IND, submissions, initiation of clinical trials and timingof expected clinical results for our lead drug candidate, ACR-368, ACR-2316, and our other future drugcandidates;•the timing of any submission of filings for regulatory approval of, and our ability to obtain and maintainregulatory approvals for, ACR-368, ACR-2316, and any other drug candidates for any indication;•our ability to identify patients with the cancers treated by our drug candidates, and to enroll patients intrials;•our expectations regarding the size of the patient populations, market acceptance and opportunity forand clinical utility of our drug candidates, if approved for commercial use;•our manufacturing capabilities and strategy, including the scalability and commercial viability of ourmanufacturing methods and processes;•our expectations regarding the scope of any approved indication for ACR-368, ACR-2316, or any otherdrug candidate;•our ability to successfully commercialize our drug candidates;•our ability to leverage our proprietary precision medicine platform, Acrivon Predictive PrecisionProteomics, or AP3TM, to identify and develop future drug candidates;•our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for orability to obtain additional funding before we can expect to generate any revenue from drug sales;•our ability to establish or maintain collaborations or strategic relationships;•our ability to identify, recruit and retain key personnel;•our reliance upon intellectual property licensed from third par